{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:12:24Z","timestamp":1789726344665,"version":"4.0.1"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ajem.2025.06.021","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T06:42:59Z","timestamp":1749883379000},"page":"48-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Incidence of significant adverse events within 24\u00a0h following administration of tenecteplase or alteplase for treatment of acute ischemic stroke: A multi-center, single-enterprise, retrospective study"],"prefix":"10.1016","volume":"96","author":[{"given":"Sierra M.","family":"Greiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin E.","family":"Marrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank S.","family":"Rigelsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan P.","family":"Wirick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn M.","family":"Sperger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanda","family":"Mullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef Hadib","family":"Nissan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Hromulak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Mohseni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajem.2025.06.021_bb0005","series-title":"About stroke","author":"American Stroke Association","year":"2023"},{"issue":"12","key":"10.1016\/j.ajem.2025.06.021_bb0010","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.ajem.2025.06.021_bb0015","series-title":"Package insert","author":"TNKase\u00ae (Tenecteplase)","year":"2024"},{"key":"10.1016\/j.ajem.2025.06.021_bb0020","series-title":"Package insert","author":"Activase\u00ae (Alteplase)","year":"2022"},{"key":"10.1016\/j.ajem.2025.06.021_bb0025","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ibneur.2023.03.001","article-title":"Feasibility of switching from alteplase to tenecteplase for stroke thrombolysis - a retrospective cohort analysis","volume":"14","author":"Sj\u00f6gren","year":"2023","journal-title":"IBRO Neurosci Rep"},{"issue":"4","key":"10.1016\/j.ajem.2025.06.021_bb0030","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/23969873221113729","article-title":"Treatment times, functional outcome, and hemorrhage rates after switching to tenecteplase for stroke thrombolysis: insights from the TETRIS registry","volume":"7","author":"Gerschenfeld","year":"2022","journal-title":"Eur Stroke J"},{"issue":"10","key":"10.1016\/j.ajem.2025.06.021_bb0035","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.1161\/STROKEAHA.121.035931","article-title":"Switching to Tenecteplase for stroke thrombolysis: real-world experience and outcomes in a regional stroke network","volume":"52","author":"Mahawish","year":"2021","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.ajem.2025.06.021_bb0040","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s11239-022-02730-5","article-title":"The efficacy and safety of tenecteplase versus alteplase for acute ischemic stroke: an updated systematic review, pairwise, and network meta-analysis of randomized controlled trials","volume":"55","author":"Abuelazm","year":"2023","journal-title":"J Thromb Thrombolysis"},{"issue":"17","key":"10.1016\/j.ajem.2025.06.021_bb0045","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa1716405","article-title":"Tenecteplase versus Alteplase before Thrombectomy for ischemic stroke","volume":"378","author":"Campbell","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajem.2025.06.021_bb0050","unstructured":"Wang Y, Li S, Pan Y, et al. n.d. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial [published correction appears in Lancet. 2023 Apr 1;401(10382):1078]. Lancet"},{"key":"10.1016\/j.ajem.2025.06.021_bb0055","series-title":"Lexi-Drugs. Lexicomp Online","author":"Tenecteplase","year":"2024"},{"key":"10.1016\/j.ajem.2025.06.021_bb0060","series-title":"Lexi-Drugs. Lexicomp Online","author":"Alteplase","year":"2024"},{"issue":"2","key":"10.1016\/j.ajem.2025.06.021_bb0065","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s12028-021-01348-4","article-title":"The routine follow-up head CT: is it still a necessary step in the thrombolysis pathway?","volume":"36","author":"Llinas","year":"2022","journal-title":"Neurocrit Care"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675725004036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675725004036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T21:24:15Z","timestamp":1759872255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675725004036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":13,"alternative-id":["S0735675725004036"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2025.06.021","relation":{},"ISSN":["0735-6757"],"issn-type":[{"value":"0735-6757","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of significant adverse events within 24\u00a0h following administration of tenecteplase or alteplase for treatment of acute ischemic stroke: A multi-center, single-enterprise, retrospective study","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2025.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}